Dr. Paul F Page, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 22890 Virgil Goode Hwy, Boones Mill, VA 24065 Phone: 540-334-5511 Fax: 540-334-3174 |
News Archive
Arena Pharmaceuticals, Inc. announced today that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of October 22, 2010, for the review of the lorcaserin New Drug Application (NDA). The acceptance of the lorcaserin NDA filing confirms that the application is sufficiently complete to permit a substantive review, and the PDUFA date is the goal date for the FDA to complete its review of the NDA.
Targeting deadly, drug-resistant bacteria poses a serious challenge to researchers looking for antibiotics that can kill pathogens without causing collateral damage in human cells.
Many low-income countries are unlikely to reach the Millennium Development Goal (MDG) health targets set for 2015; the main reasons for this are fragile health systems and insufficient investments in understanding how to strengthen them, suggest authors of a Public Health article in this week's issue of THE LANCET.
Scientists have discovered that drugs used to treat HIV may also one day become lifesaving drugs targeted at parasitic diseases such as leishmaniasis and malaria.
The European Collaborative Oncological Gen-‐Environmental Study (COGS) project, whose main goal is to decipher the complex genetic bases of breast, prostate and ovarian cancers, publishes a total of 12 research articles in several prestigious journals, including Nature Genetics, Nature Communications, The American Journal of Human Genetics and PLOS Genetics.
› Verified 5 days ago